What’s getting R&D attention? The impact of upcoming regulations, A.I., new cybersecurity risks, developments in battery power and innovation, collaborative efforts, and other impacts on the industry in the year ahead.
How will 2025 rise to the challenge of meeting the demand for personalized healthcare? A perspective on the transformative advancements of 2024—highlighting the impact of AI, robotics, and digital health as they begin to reshape the healthcare landscape.
Cardiovascular conditions are the leading cause of death. Fortunately, industry leaders are discovering innovative ways to diagnose and treat them. See how mobile apps and AI will change this field in 2025 and beyond.
MTI Viewpoints are insights shared by industry relative to healthcare and the advancement of medical technology.
Billions of dollars are lost annually in medical billing errors resulting from data entry mistakes, outdated coding practices, and duplicated charges. Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing the process of claims processing, diagnostics, eliminating errors, streamlining workflow, and increasing the accuracy of claims submissions. Together with human oversight to ensure precision and safety, AI augments healthcare professionals to improve patient care and outcomes.
AI and real-time data enhance care efficiency and access. And with healthcare workers in short supply, the rapid advancements in AI, IoMT, and related innovation offer patient access freedom, enhanced care delivery, and better outcomes.
Law firm, Hogan Lovells, analyses the implications of the AI Act for the Medtech sector and highlight a number of key challenges for medical device manufacturers and their partners in aligning conformity routes for their products under the AI Act.
In a multi-year agreement, Zimmer Biomet will commercialize RevelAi Health’s patient care-management platform, care team dashboard for providers, and any future products or services.
As regulatory bodies increasingly recognize the richness and value of RWE, particularly in informing the benefit-risk profile of devices from real-world environments, MedTech companies are turning to advanced analytical tools to navigate this new landscape efficiently.
Payers demand robust evidence that molecular diagnostics and AI/ML technologies demonstrate clear ability to improve overall patient health or healthcare economics even if the technologies themselves don’t directly deliver the final outcome. This disconnect between a technology’s function and the desired long-term impact creates a hurdle for [innovators] to overcome when convincing payers of their value proposition.
